Startup of the Week: Wayakit, the biotech firm helping travelers beat odors and stains

1 / 3
KAUST Ph.D students Sandra Medina and Luisa Javier are avid travelers who have come up with a pocket-sized product that deals with both odors and stains on fabrics. (Photo by Huda Bashatah)
2 / 3
KAUST Ph.D students Sandra Medina and Luisa Javier are avid travelers who have come up with a pocket-sized product that deals with both odors and stains on fabrics. (Photo by Huda Bashatah)
3 / 3
KAUST Ph.D students Sandra Medina and Luisa Javier are avid travelers who have come up with a pocket-sized product that deals with both odors and stains on fabrics. (Photo by Huda Bashatah)
Short Url
Updated 10 December 2019

Startup of the Week: Wayakit, the biotech firm helping travelers beat odors and stains

  • Wayakit leaves the clothes clean and fresh again

JEDDAH: Wayakit is a biotechnology start-up incubated by King Abdullah University of Science and Technology (KAUST).

KAUST Ph.D students Sandra Medina and Luisa Javier are avid travelers who have come up with a pocket-sized product that deals with both odors and stains on fabrics, leaving the cloths clean and fresh again.

Wayakit is also gentler on fabrics because traditional laundry eventually damages them, said Javier, who first moved to Saudi Arabia from Mexico ten years ago.

Her business partner, Sandra Medina, who came from Colombia to study at KAUST, explained to Arab News how Wayakit works. “You just spray the smelly area twice and you’re good to go. In the case of stains, you spray twice and then pat dry it with a tissue and it will disappear,” she said.

The idea for the product came during a trip for a conference two years ago when the travelers realized their luggage was lost “We had to present with our dirty, seven-hours’ flight clothes,” Javier told Arab News.

“We started looking into the possibility then, because there’s not a proper solution to doing laundry while traveling,” she said.

 

They decided they needed to come up with a product that was not pricey, was easy to carry, and did the job by removing stains and bad odors “on-the-go.”

 

 

The duo began by interviewing more than 100 travelers of 23 different nationalities to find out if this was a common issue that travelers struggled with.

 

“From the Entrepreneurship Center at KAUST, we learned the importance of listening first to the customers before designing any product,” said Medina. From these interviews, Wayakit team got the product requirements and then moved into the lab to start working on the formulation of Wayakit. “The amazing facilities and labs in KAUST helped us to speed up the creation of our first prototype. After this, the same KAUST community was the people who first tried Wayakit and gave us feedback. “In KAUST we do not only have state-of-the-art labs, but also a whole entrepreneurial ecosystem,” Medina added.

Wayakit is different from its competitors in that it contains no toxic chemicals, and covers a broader spectrum in covering stains — it is two products in one. It also contains anti-bacterial properties, acting as a sanitizer that “removes all the stains that occur on a day-to-day basis as well as being an odor remover,” Javier said.

The pair went for a biotechnology-based formula that excluded the usage of oxidizers and focused on more organic compounds. “Even the anti-bacterial properties are not toxic as we incorporated these in an environmentally friendly formulation,” she said.

The Wayakit founders had to rigorously test their product, dealing with different types of sweat and stains to perfect their spray. “We had to give testers to travelers to try it out and had to listen to their feedback, then went back to the lab to improve it, in order to make sure the product was as promised.”

Medina said KAUST’s mentorship had also helped their company to develop. “KAUST for us is a catalyst of entrepreneurship and has given us a lot of room to grow our start-up Wayakit,” she said.

KAUST helped Wayakit by giving the advice and support from the start. From entrepreneurial courses to teaching the concepts of building a brand, KAUST encouraged Wayakit to grow from a scientific outlook and helped the founders to better understand the customer.

“As foreigners, it was difficult for us to understand the logistics and procurement of shipping and importing here in Saudi Arabia. KAUST has helped us to face that hurdle in order to be able to reach all our clients in the MENA region and worldwide,” Medina said. “Beyond helping travellers, our mission is to change the way how laundry is commonly done. We found a way to effectively wash clothes reducing water and energy consumption,” Javier said. 

Wayakit has recently began selling in Jeddah’s Homegrown Market, chosen because it is “a Middle Eastern brand store with unique ambience,” said Medina.
 


Major Saudi research center prepares to take part in advanced COVID-19 vaccine trials

Updated 22 September 2020

Major Saudi research center prepares to take part in advanced COVID-19 vaccine trials

  • Ministry of Health and King Abdullah International Medical Research Center have been working with two Chinese drug companies

JEDDAH: King Abdullah International Medical Research Center (KAIMRC) in Saudi Arabia is preparing to take part in advanced trials of one or two COVID-19 vaccines.

About 40 potential vaccines are being tested on humans, nine of which are at the advanced stage of clinical trials to evaluate their safety and effectiveness in protecting people against a virus that has infected more than 31 million people around the world.

The center confirmed its readiness to cooperate with the Kingdom’s Ministry of Health and the Saudi Food and Drug Authority (SFDA) and participate in tests of one or two of the nine vaccines that are in the third phase of clinical trials, during which large-scale testing on humans takes place.

Dr. Naif Al-Harbi, the head of KAIMRC’s drug-development unit, told Al-Ekhbariya TV news channel that it is unprecedented to have nine vaccines in stage three of clinical trials so soon, less than a year, after the emergence of a new virus.

“Approval or disapproval of any drug normally follows the third stage of its clinical trials, which is the last stage,” he added. “Since the pandemic, KAIMRC has been in continuous contact with a number of drug companies in four countries (that are developing vaccines).”

KAIMRC has been working with one Chinese pharmaceutical company in particular to help evaluate and accelerate the development of its vaccine, he said.

“Over the past two months, we have been in contact with Sinovac to scientifically evaluate its product, in term of the tests on animals and a study of the results of stages one and two on humans,” Al-Harbi said.